In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more.
Read the full coverage here:
Addition of tumor treating fields to standard therapy extends OS in advanced lung cancer
Atezolizumab-bevacizumab confers ‘much higher than usual’ survival rates in NSCLC subset
Lung cancer screening leads to more stage I, less stage IV disease incidence
Anti-TIGIT regimens improve outcomes vs. anti-PD-1 alone in lung cancer subgroup
FDA approves adagrasib for certain adults with non-small cell lung cancer
References:
Johnson ML, et al. Abstract 397600. Presented at: ASCO Plenary Series: December 2022 Session; Dec. 20, 2022.
Provencio M, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5959.
Vachani A, et al. J Thorac Oncol. 2022;doi:10.1016/j.jtho.2022.08.011.
